Videos

Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.

John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.

Randall A. Oyer, MD, discusses the importance of the ACCC community during the unprecedented coronavirus disease 2019 pandemic.

A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.

Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.

Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.

Kami J. Maddocks, MD, discusses the role of tafasitamab and lenalidomide following the approval of this agent as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Robert Alter, MD, of John Theurer Cancer Center, describes the rationale for treating a 58-year-old male with advanced renal cell carcinoma with the combination of lenvatinib and everolimus following progression on first-line therapy.

Robert L. Coleman, MD, discusses the next steps for tisotumab vedotin following the presentation of findings from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study in patients with previously treated recurrent or metastatic cervical cancer.